JPMorgan Chase & Co. reduced its stake in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 73.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,481 shares of the company's stock after selling 64,471 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.11% of PetMed Express worth $86,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in PetMed Express in the second quarter worth about $46,000. Independent Advisor Alliance bought a new position in shares of PetMed Express during the 3rd quarter valued at approximately $106,000. Sei Investments Co. increased its holdings in PetMed Express by 8.3% in the 2nd quarter. Sei Investments Co. now owns 44,220 shares of the company's stock worth $179,000 after acquiring an additional 3,400 shares in the last quarter. Squarepoint Ops LLC bought a new stake in PetMed Express during the 2nd quarter worth approximately $273,000. Finally, Bleakley Financial Group LLC purchased a new position in PetMed Express during the third quarter valued at approximately $279,000. 73.33% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of PetMed Express from a "hold" rating to a "buy" rating in a research note on Tuesday, November 12th.
Check Out Our Latest Analysis on PETS
PetMed Express Stock Performance
Shares of PetMed Express stock traded down $0.18 during trading hours on Friday, hitting $5.32. The company's stock had a trading volume of 217,108 shares, compared to its average volume of 224,648. The company has a market cap of $109.91 million, a PE ratio of -88.67 and a beta of 0.70. The business has a 50 day moving average price of $5.12 and a two-hundred day moving average price of $4.29. PetMed Express, Inc. has a 12-month low of $2.90 and a 12-month high of $6.85.
PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.17. PetMed Express had a negative return on equity of 1.00% and a negative net margin of 0.37%. The business had revenue of $59.57 million during the quarter, compared to the consensus estimate of $66.02 million. As a group, research analysts anticipate that PetMed Express, Inc. will post 0.24 earnings per share for the current year.
Insider Transactions at PetMed Express
In other news, Director Leslie C.G. Campbell acquired 15,000 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average price of $5.38 per share, for a total transaction of $80,700.00. Following the completion of the transaction, the director now directly owns 70,000 shares in the company, valued at approximately $376,600. This trade represents a 27.27 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.10% of the company's stock.
About PetMed Express
(
Free Report)
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Further Reading

Before you consider PetMed Express, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.
While PetMed Express currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.